Hospital-acquired pneumonia (HAP) stands as one of the most significant challenges in patient care, representing a leading cause of morbidity among hospitalized patients. This formidable infection not only contributes to extended hospital stays but also leads to increased healthcare costs and a greater burden on healthcare systems. Companies like TAXIS Pharmaceuticals have the potential to transform outcomes for patients battling this condition.
As we navigate the complexities of modern medicine, a quiet threat remains: multi-drug resistant gonorrhea (MDRSG, commonly referred to as Super Gonorrhea), a rapidly spreading, deadly, and highly resistant strain of Neisseria gonorrhoeae. Super gonorrhea is a prime example of how bacteria can outsmart our best defenses. At TAXIS, we are diving headfirst into the science of combating antimicrobial AMR.
Understanding the mechanisms behind antibiotic resistance reveals the pressing need for innovative solutions in the pharmaceutical landscape. Presenting TAXIS Pharmaceuticals' Commitment to Innovation: TXA709. TAXIS is dedicated to developing novel therapies that specifically target resistant strains of bacteria.
© 2025 TAXIS Pharmaceuticals, Inc.
Frank Carlo Pasqualone, MBA
Joe DePinto, MBA
Gregory G. Mario, MBA, President and CEO